Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cpg-52852. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 known ✓ | Q9NYK1 | 20/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cpg-52852 SCHEMBL29371102 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL29182347 | 0.97 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL18429392 | 0.93 | TLR7 (0.86) | TLR7TLR8 | |
| SCHEMBL483689 | 0.92 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL29852269 | 0.92 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL18680036 | 0.92 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL728467 | 0.91 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL2744306 | 0.91 | TLR7 (0.83) | TLR7TLR8 | |
| SCHEMBL3973102 | 0.90 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL3975772 | 0.90 | TLR7 (0.82) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 718 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270316-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-08-28 | — | — | US | claimed |
| US-20250235533-A1 | INJECTABLE PROLONGED-RELEASE HYDROGEL FORMULATIONS OF TOLL-LIKE RECEPTOR AGONISTS FOR INTRATUMORAL INJECTION TO INCREASE IMMUNOTHERAPY RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-07-24 | — | — | US | claimed |
| EP-4559479-A2 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-28 | — | — | EP | claimed |
| EP-4543494-A1 | BETA-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | Sutro Biopharma, Inc. (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119855614-A | Beta-glucuronide linker-payload, protein conjugates thereof and methods thereof | 苏特罗生物制药公司 | 2025-04-18 | — | — | CN | claimed |
| WO-2025080869-A1 | PANCREATIC CANCER IMMUNOTHERAPY USING CATIONIC LIPID AND POLYMER NANOCARRIERS FOR CO-DELIVERY OF KRAS NEOANTIGENS AND STING AND/OR OTHER IMMUNOMODULATORS TO BOOST THE CANCER IMMUNITY CYCLE AND TREAT LIVER METASTASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025072371-A2 | HIGHLY ACTIVE MYELOID THERAPY | THE GENERAL HOSPITAL CORPORATION (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2024006272-A9 | β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | SUTRO BIOPHARMA, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| CN-117881419-A | Pharmaceutical combination and use thereof | 天津立博美华基因科技有限责任公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2024006272-A1 | β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | SUTRO BIOPHARMA, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| EP-1455700-A4 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES CO (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1719511-A2 | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide, a pharmaceutical composition comprising the same and use thereof | 3M Innovative Properties Company (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2006074045-A2 | IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | claimed |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-08 | — | — | US | claimed |
| US-6924293-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-02 | — | — | US | claimed |
| WO-2005003064-A2 | SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-01-13 | — | — | WO | claimed |
| EP-1455700-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M Innovative Properties Company (US) | 2004-09-15 | — | — | EP | claimed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | claimed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | claimed |
| WO-2003043572-A2 | METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.